BlackRock Takes $2.8 Billion CenterWell Stake as Humana Restructures Clinic Financing

Humana Inc. has agreed to replace private equity firm Welsh, Carson, Anderson & Stowe (WCAS) with BlackRock as the majority investor in a joint venture holding nearly 150 CenterWell Senior Primary Care clinics, valuing the outgoing investor’s equity stake at approximately $2.8 billion.

The transaction will transfer WCAS’s ownership to funds and accounts managed by BlackRock subsidiary HPS Investment Partners. Humana’s CenterWell division will retain minority ownership and operational control, while the insurer expects to reduce balance sheet liabilities and secure additional capital for clinic expansion.

The agreement represents a significant restructuring of healthcare investment ownership, replacing a traditional private equity sponsor with a major alternative asset manager while preserving Humana’s operating relationship with its clinics.

BlackRock Replaces WCAS After Seven-Year Partnership

WCAS helped finance CenterWell’s expansion over seven years through joint ventures that separated clinic ownership from day-to-day operations.

Under the new arrangement, BlackRock will acquire WCAS’s equity interest, valued at approximately $2.8 billion. That figure represents the outgoing investor’s stake rather than cash proceeds payable to Humana.

According to Humana’s official transaction announcement, the joint venture expects to deploy additional capital over the next two years to support existing operations, establish clinics and pursue acquisitions.

CenterWell will continue operating the facilities, maintaining continuity across its senior-focused primary care network.

The transaction is expected to close during the fourth quarter of 2026, subject to regulatory approvals and customary conditions.

Revised Structure Reduces Humana’s Financial Obligations

A central feature of the agreement is the removal of put options embedded in the previous WCAS partnerships.

Those arrangements created financial obligations because investors could require Humana to purchase their interests under specified conditions.

The replacement venture eliminates BlackRock’s equivalent put right, allowing Humana to anticipate a substantial reduction in reported liabilities.

However, the restructuring does not eliminate every financial commitment.

Humana’s SEC Form 8-K filing confirms that CenterWell has agreed to minimum-return protections for BlackRock, creating a derivative instrument that will be recognized at fair value.

For investors, the distinction matters: the transaction changes Humana’s financial exposure rather than removing all potential obligations associated with outside capital.

Humana expects the revised terms to reduce its overall cost of capital.

CenterWell Retains Future Acquisition Rights

The agreement establishes a defined timetable for potential changes in clinic ownership. Beginning in 2028, CenterWell can elect to purchase clinics from the joint venture.

If clinics remain under joint ownership at the end of 2033, BlackRock may initiate a sale process, although CenterWell retains the right to submit the first acquisition offer.

This arrangement gives Humana flexibility to expand the network before deciding whether to increase direct ownership. The structure also creates a potential future liquidity pathway for BlackRock without requiring an immediate exit.

Healthcare Private Capital Strategies Continue to Evolve

BlackRock’s investment follows other healthcare transactions involving alternative asset managers, including the private credit lender takeover of Affordable Care (), which involved approximately $1 billion in debt reduction.

Although the structures differ, both transactions demonstrate how private capital providers can influence healthcare ownership and financing beyond conventional buyouts.

The CenterWell agreement also follows Humana’s planned divestiture of its minority interest in hospice provider Gentiva to an investor consortium including BlackRock.

Elsewhere, the $1.4 billion Ares-backed Spire Healthcare takeover illustrates continued institutional interest in healthcare operating assets.

For private-market investors, CenterWell offers exposure to an established clinical network with future expansion opportunities and contractual exit provisions.

For Humana shareholders, the immediate financial considerations are reduced liabilities, future capital requirements and the cost of BlackRock’s return protections.

Humana said the agreement is not expected to materially affect its 2026 adjusted earnings guidance, which remains at least $9 per share.